Sign in

CIK 0001812364 · Large accelerated filer

Relay Therapeutics, Inc.

Sign in to watch
Ticker
RLAY
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-370-8837
Business address
60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$120,165,474
in 11 filings, $3.7M under 10b5-1 plans

Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. SVF Pauling (Cayman) Ltd −$116.4M 10% owner sold 22% of stake
  2. Patel Sanjiv −$2.8M President and CEO sold 23% of stake
  3. Catinazzo Thomas −$692K Chief Financial Officer sold 26% of stake
  4. Bergstrom Donald A −$204K President, R&D sold 3% of stake
  5. Rahmer Peter −$104K See remarks sold 2% of stake

Reading 98 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-06-09 INGRAM DOUGLAS S Director Grant or award · Stock Option (Right to Buy) +32,947 32,947
2026-06-09 Murcko Mark Director Grant or award · Stock Option (Right to Buy) +32,947 32,947
2026-05-14 Catinazzo Thomas Chief Financial Officer Sale 10b5-1 −17,717 $12.86 $228K 195,178
2026-04-28 Catinazzo Thomas Chief Financial Officer Sale −972 $14.79 $14K 212,895
2026-04-28 Rahmer Peter See remarks Sale −753 $14.79 $11K 275,857
2026-04-28 Bergstrom Donald A President, R&D Sale −1,490 $14.79 $22K 418,557
2026-04-09 Catinazzo Thomas Chief Financial Officer Option exercise 10b5-1 +1,800 $5.22 $9K 215,667
2026-04-09 Catinazzo Thomas Chief Financial Officer Sale 10b5-1 −1,800 $15.00 $27K 213,867
2026-04-09 Catinazzo Thomas Chief Financial Officer Option exercise · Stock Option (Right to Buy) 10b5-1 −1,800 61,563
2026-04-07 Catinazzo Thomas Chief Financial Officer Sale 10b5-1 −17,717 $13.01 $230K 213,867
2026-03-09 Catinazzo Thomas Chief Financial Officer Sale 10b5-1 −17,717 $10.06 $178K 231,584
2026-01-28 Bergstrom Donald A President, R&D Sale −2,686 $8.45 $23K 420,047
2026-01-28 Rahmer Peter See remarks Sale −1,354 $8.45 $11K 276,610
2026-01-28 Catinazzo Thomas Chief Financial Officer Sale −1,695 $8.45 $14K 249,301
2026-01-27 Bergstrom Donald A President, R&D Sale −18,895 $7.62 $144K 422,733
2026-01-27 Rahmer Peter See remarks Sale −11,684 $7.62 $89K 277,964
2026-01-27 Catinazzo Thomas Chief Financial Officer Sale −13,820 $7.62 $105K 250,996
2026-01-13 Bergstrom Donald A President, R&D Grant or award · Stock Option (Right to Buy) +575,000 575,000
2026-01-13 Rahmer Peter See remarks Grant or award · Stock Option (Right to Buy) +475,000 475,000
2026-01-13 Patel Sanjiv President and CEO Grant or award · Stock Option (Right to Buy) +1,450,000 1,450,000

Page 3 of 17 · 329 trades